Reducing Sedentary Time in Patients With Heart Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02911493

Acronym

Rest-HF

Enrollment

Registered

2016-09-22

Start date

2016-09-30

Completion date

2019-04-30

Last updated

2019-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

sedentary time, number of steps/day, mobility, disability

Brief summary

To determine the change in sedentary time and number of steps/day for older patients with heart failure at risk for mobility disability who receive a program to decrease sedentary behavior versus a standard program to increase exercise.

Interventions

BEHAVIORALReducing Sedentary Behavior

The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.

BEHAVIORALPhysical Activity Group

The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

65 Years to 100 Years

Healthy volunteers

Inclusion criteria

* NYHA II-IV, * Age ≥ 65, * SPPB score of \> 4 and ≤ 10 of 12, * and deemed (by 1° cardiologist) to be at maximal tolerated dose of heart failure medication (ACE-inhibitor (ACE-I)/angiotensin receptor blocker and beta blocker (BB) for patients with HF with reduced ejection fraction (HFrEF), and * blood pressure controlled for HF with preserved ejection fraction (HFpEF) according to the American Heart Failure Association HF guidelines.

Exclusion criteria

* Patients requiring medication titration such as ACE-I or BB, (will return to their cardiologist and be eligible after 3 months of stable medication.) * Oxygen dependent lung disease, * Orthopedic or neurologic disease that severely limits mobility, * Active cancer diagnosis except non-melanoma skin cancer, * Geriatric Depression Scale (GDS) score of ≥ 9 , * Limited life-expectancy of \<6 months, * Known dementia or disease that effects ability to learn/follow directions, or * Failed MiniCog test.

Design outcomes

Primary

Measure	Time frame
Number of Subjects that are more active than Control.	Monthly for 3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026